Press releases
- Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
- Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
- Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
- Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
- Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
- Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
- Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
- Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
More ▼
Key statistics
On Friday, ACADIA Pharmaceuticals Inc (ACAD*:MEX) closed at 252.17, 0.00% above its 52-week low of 252.17, set on Jul 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 252.17 |
Low | 252.17 |
Bid | -- |
Offer | -- |
Previous close | 282.73 |
Average volume | 0.00 |
---|---|
Shares outstanding | 165.22m |
Free float | 164.38m |
P/E (TTM) | -- |
Market cap | 2.58bn USD |
EPS (TTM) | -0.0129 USD |
Data delayed at least 20 minutes, as of Jul 14 2023 12:30 BST.
More ▼